

Xiaomei Yuan

PATENT AGENT

Patents and
Innovations
San Diego

xyuan@wsgr.com
858-350-2256

FOCUS AREAS

Biotech
Life Sciences
Patents and Innovations

EXPERIENCE

Dr. Xiaomei Yuan is a patent agent in the San Diego office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. Xiaomei assists with the preparation and prosecution of patent applications in the fields of biology and biotechnology. She has an extensive research background in cancer immunotherapy and autoimmunity, which informs her work overall as a patent agent and scientist.

Prior to joining the firm, Xiaomei was a research scientist and a team leader at a biopharmaceutical company, where she conducted, managed, and led many projects including CAR-T, gamma-delta TCR-T cell therapy, and iPSC-derived CAR-NK cell therapy.

Xiaomei received her Ph.D. in Microbiology and Immunology from University of Miami, where her work focused on the role of IL-2R signaling in regulatory T cell subsets. Following graduation, she pursued postdoctoral research at UC San Diego, investigating immune regulation and regulatory T cells in the context of Type 1 Diabetes.

CREDENTIALS

Education

- Ph.D., Microbiology and Immunology, University of Miami, 2014
- M.S., Immunology, Huazhong University of Science and Technology, Tongji Medical College, 2007
- B.S., Preventive Medicine, Huazhong University of Science and Technology, Tongji Medical College, 2004

Admissions

- U.S. Patent and Trademark Office

INSIGHTS

Select Publications

- Co-author with Z. Chen, et al., "Antibody- based binding domain fused to TCR γ chain facilitates T cell cytotoxicity for potent anti-tumor response," *Oncogenesis*, 2023
- Co-author with B. Yang, et al., "TCF1 and LEF1 control Treg competitive survival and Tfr development to prevent autoimmune diseases," *Cell Rep*, 2019
- Co-author with Y. Dong, et al., "CD122 blockade restores immunological tolerance in autoimmune type 1 diabetes via multiple mechanisms," *JCI Insight*, 2018
- Co-author with B. Yang, et al., "CR1g, a tissue-resident macrophage specific immune checkpoint molecule, promotes immunological tolerance in NOD mice, via a dual role in effector and regulatory T cells," *Elife*, 2017
- Co-author with K.H. Toomer, et al., "Developmental progression and interrelationship of central and effector regulatory T cell subsets," *J Immunol*, 2016

- Co-author with S. Kanagavelu, et al., “TIR-domain-containing adapter-inducing interferon- β (TRIF) regulates Th17-mediated intestinal immunopathology in colitis,” *Mucosal Immunol*, 2015
- Co-author with M.J. Dee, et al., “IL-2R β -dependent signaling and CD103 functionally cooperate to maintain tolerance in the gut mucosa,” *J Immunol*, 2015
- Co-author with G. Cheng, et al., “The importance of regulatory T-cell heterogeneity in maintaining self- tolerance,” *Immunol Rev*, 2014
- Co-author with G. Cheng, et al., “IL-2 receptor signaling is essential for the development of Klrp1+ terminally differentiated T regulatory cells,” *J Immunol*, 2012
- Co-author with T.R. Malek, “Cellular and molecular determinants for the development of natural and induced regulatory T cells,” *Hum Immunol*, 2012

TECHNICAL FLUENCY

Biological Sciences and Biotechnology

- Antibody
- Antigen presentation
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell therapy
- Cellular immunology
- Immuno-oncology
- Immunobiology
- Immunology
- Stem cell biology
- T and B cell biology
- T cell biology
- T cell immunology

Therapeutics and Drug Discovery

- CRISPR
- Gene editing
- Immunotherapy targets
- Vaccines

Miscellaneous

- Cancer